Stryker names Spencer Stiles CEO and Stryker stock gains 1.05 percent

Published on 10/07/2026 at 15:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 6.59 billion, up from USD 6.02 billion. Stryker stock costs EUR 251.10 on October 7, 2026 after EUR 248.50.

Pop-Art-Comic zeigt Chirurgen mit robotergestütztem OP-System in leuchtenden Farben — Pop-Art-Comic-Illustration einer farbenfrohen Roboterchirurgie-Szene verbildlicht anschaulich das Geschäftsfeld von Stryker Corp. US8636671013 heute, Illustration mit AI erstellt.

Stryker Corp. (ISIN US8636671013) was trading at EUR 251.10 at Lang & Schwarz on October 7, 2026 at 3:35 p.m. CEST, plus 1.05 percent versus the Xetra close of EUR 248.50 on October 6, 2026. As Investing.com reported on October 6, 2026, Spencer Stiles will become chief executive officer on January 1, 2027, while Kevin Lobo moves to executive chair.

Succession sets the next test

The leadership change is part of a planned succession process, with Stiles also joining Stryker's Board of Directors on January 1, 2027. Lobo has led the company since 2012, giving the transition a direct link to the group's long-term operating record.

Investing.com reported on October 6, 2026, that Needham reiterated a Buy rating and a USD 418.00 price target after the succession plan. The contrast with Truist is material: Investing.com reported on October 6, 2026, that Truist cut its target from USD 340.00 to USD 310.00 while maintaining Hold.

Revenue keeps the operating case intact

Stryker reported USD 6.59 billion in revenue for the second quarter of 2026, up from USD 6.02 billion in the second quarter of 2025, according to Business Insider on October 3, 2026. The comparison shows that the CEO handover is arriving alongside continued year-over-year sales expansion, even as analysts debate the pace of future growth.

Yahoo Finance reported on October 6, 2026, that Stryker is scheduled to release third-quarter 2026 results on October 29, 2026. Analysts cited in the report expect USD 6.638 billion in revenue and earnings per share of USD 3.57 for that quarter.

Stock stays below its yearly high

The EUR 251.10 Lang & Schwarz price sits within a 52-week range of EUR 210.60 to EUR 337.30 for the EUR listing, while the company's market capitalization is EUR 96.3 billion as of October 7, 2026. The price is 25.55 percent below the 52-week high, calculated from the same EUR range and reference price.

Stryker's primary listing is on the NYSE under ticker SYK, and its medical-device business spans orthopaedics, MedSurg and neurotechnology. The next reporting date gives the market a defined checkpoint for judging whether the leadership transition is being matched by the revenue trajectory.

Price source: Lang & Schwarz. Stryker was trading at EUR 251.10 on October 7, 2026 at 3:35 p.m. CEST, plus 1.05 percent versus the Xetra close of EUR 248.50 on October 6, 2026. The further course of trading is shown by the continuously updated real-time quote of Stryker stock.